Leerink Partners Maintains Quanterix(QTRX.US) With Buy Rating
Leerink Partners Sticks to Its Buy Rating for Quanterix (QTRX)
Quanterix: Strong Growth in Accelerator Services and Strategic Expansion Drive Buy Rating
Quanterix Analyst Ratings
TD Cowen Maintains Quanterix(QTRX.US) With Hold Rating, Maintains Target Price $16
Scotiabank Maintains Quanterix(QTRX.US) With Buy Rating, Maintains Target Price $28
Analysts Have Conflicting Sentiments on These Healthcare Companies: Quanterix (QTRX), Nevro Corp (NVRO) and Tempest Therapeutics (TPST)
Quanterix (QTRX) Gets a Buy From Scotiabank
TD Cowen Maintains Quanterix(QTRX.US) With Hold Rating, Raises Target Price to $16
Leerink Partners Maintains Quanterix(QTRX.US) With Buy Rating
Leerink Partners Maintains Quanterix(QTRX.US) With Buy Rating
Leerink Partners Sticks to Its Buy Rating for Quanterix (QTRX)
Analysts Offer Insights on Healthcare Companies: Quanterix (QTRX), Doximity (DOCS) and Warby Parker (WRBY)
Quanterix Price Target Cut to $28.00/Share From $32.00 by Scotiabank
Scotiabank Keeps Their Buy Rating on Quanterix (QTRX)
Quanterix Analyst Ratings
Hold Rating on Quanterix Amid Modest Sales Performance and Market Uncertainty
Analysts' Top Healthcare Picks: Trevi Therapeutics (TRVI), Quanterix (QTRX)
Scotiabank Maintains Quanterix(QTRX.US) With Buy Rating, Maintains Target Price $32
Quanterix Analyst Ratings
No Data